✦ LIBER ✦

Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial

✍ Scribed by Lawitz, Eric; Poordad, Fred F; Pang, Phillip S; Hyland, Robert H; Ding, Xiao; Mo, Hongmei; Symonds, William T; McHutchison, John G; Membreno, Fernando E

Book ID: 121351187
Publisher: The Lancet
Year: 2014
Tongue: English
Weight: 400 KB
Volume: 383
Category: Article
ISSN: 0140-6736
DOI: 10.1016/S0140-6736(13)62121-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Sofosbuvir with pegylated interferon alf

Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial

✍ Kowdley, Kris V; Lawitz, Eric; Crespo, Israel; Hassanein, Tarek; Davis, Mitchell 📂 Article 📅 2013 🏛 The Lancet 🌐 English ⚖ 241 KB

Sofosbuvir in combination with peginterf

Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial

✍ Lawitz, Eric; Lalezari, Jay P; Hassanein, Tarek; Kowdley, Kris V; Poordad, Fred 📂 Article 📅 2013 🏛 The Lancet 🌐 English ⚖ 276 KB

Simeprevir plus sofosbuvir, with or with

Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study

✍ Lawitz, Eric; Sulkowski, Mark S; Ghalib, Reem; Rodriguez-Torres, Maribel; Younos 📂 Article 📅 2014 🏛 The Lancet 🌐 English ⚖ 555 KB

Efficacy of boceprevir, an NS3 protease

Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial

✍ Paul Y Kwo; Eric J Lawitz; Jonathan McCone; Eugene R Schiff; John M Vierling; Da 📂 Article 📅 2010 🏛 The Lancet 🌐 English ⚖ 378 KB

Daily dose of interferon alpha-2b and ri

Daily dose of interferon alpha-2b and ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection: a randomised controlled study

✍ GianPiero Benetti; Mauro Borzio; Giuliano Ramella; Giorgio Bellati; Silvia Fargi 📂 Article 📅 2006 🏛 Springer Milan 🌐 English ⚖ 98 KB